An internal FDA review of Amgen’s study of its cancer-killing virus talimogene laherparepvec (T-Vec), released Monday morning, raises red flags for this drug, presenting some thorny questions for the company’s regulatory team to answer.

…read more

Source: UPDATED: FDA review challenges Amgen on a questionable T-Vec study


0 No comments